Hypertension

Details

Hypertension is the most prevalent and modifiable cardiovascular risk factor, affecting 46.7% of US adults (2017–2020 NHANES). It is a leading cause of stroke, heart failure, atrial fibrillation, CKD, dementia, and all-cause mortality. Two major 2024/2025 guidelines have updated its management — the 2024 ESC Guidelines and the 2025 AHA/ACC Guidelines — with important differences in classification, risk assessment tools, and treatment targets (see ESC vs AHA comparison below).

ESC 2024 vs AHA 2025 — Key Guideline Differences

(sources/ht-esc-2024, rating: very high; sources/HT-AHA-2025, rating: very high)

Epidemiology

• Prevalence: overall 46.7%; highest in Black adults (56–57%), age 75–80 (83–85%), men (49.5%). (sources/HT-AHA-2025, rating: very high)
• HT is antecedent in 71% of HF cases; highest attributable risk factor for new-onset AF.
• Only 23% of all US adults with hypertension achieve BP control (<130/80 mmHg). (sources/rnd-aha-2024, rating: high)

Classification

ESC 2024 (3-category system): (sources/ht-esc-2024, rating: very high)

• HBPM hypertension: ≥135/85 mmHg; ABPM 24h: ≥130/80 mmHg; ABPM daytime: ≥135/85 mmHg; ABPM night-time: ≥120/70 mmHg
• Diagnosis requires out-of-office confirmation (HBPM or ABPM) or repeated office BP on a second visit
• Elevated BP category triggers risk stratification — not automatic treatment

AHA 2025 (4-category system): (sources/HT-AHA-2025, rating: very high)

• Diagnosis requires average of ≥2 readings on ≥2 separate occasions. (sources/HT-AHA-2025, rating: very high)

ESC 2024 Risk Stratification for Elevated BP

For patients with elevated BP (SBP 120–139 / DBP 70–89 mmHg): (sources/ht-esc-2024, rating: very high)

• Automatic high-risk (treat if BP ≥130/80 after 3 months lifestyle): moderate/severe CKD, established CVD (CAD, stroke, PAD, HF), HMOD, diabetes mellitus, familial hypercholesterolaemia
• Use SCORE2 (age 40–69) or SCORE2-OP (age ≥70): ≥10% 10-year CVD risk = treat
• Borderline 5–<10%: consider sex-specific risk modifiers (gestational DM, gestational HT, pre-eclampsia, preterm delivery, stillbirth, recurrent miscarriage); shared modifiers (South Asian ethnicity, premature ASCVD family history, socioeconomic deprivation, autoimmune disorders, HIV, severe mental illness)
• If still uncertain: CAC score, carotid/femoral plaque, hs-cTnT/BNP, pulse wave velocity
• <5% CVD risk OR BP 120–129/70–79: lifestyle only; reassess in 1 year
• Age <40: HMOD assessment preferred (SCORE2 not validated in this age group)
• See concepts/Hypertension-HMOD for full HMOD assessment thresholds

AHA 2025 Risk Assessment — PREVENT™ Score

• PREVENT™ (Predicting Risk of CVD EVENTs) derived from 3.2 million individuals (1992–2022); contemporary, diverse, race-free model. (sources/HT-AHA-2025, rating: very high)
• Estimates total CVD (MI + stroke + HF), not just ASCVD; applicable ages 30–79; includes eGFR, statin use, and social deprivation index (SDI).
• PCEs overpredicted risk ~2-fold; PREVENT has excellent calibration across race/ethnic groups.
• Treatment threshold: PREVENT ≥7.5% (lowered from PCE ≥10%) — initiate medication at SBP ≥130 mmHg. (sources/HT-AHA-2025, rating: very high)
• See concepts/ASCVD-Risk-Assessment for full PREVENT methodology.

Diagnosis and BP Monitoring

Treatment Thresholds — ESC 2024

• Hypertension (≥140/90 mmHg): initiate lifestyle + pharmacotherapy promptly regardless of risk (Class I, A) (sources/ht-esc-2024, rating: very high)
• Elevated BP + high CVD risk (SCORE2 ≥10% or high-risk conditions): lifestyle 3 months then add drugs if BP ≥130/80 (Class I, A)
• Elevated BP + low/medium CVD risk (<10%): lifestyle only (Class I, B)
• Elevated BP in special populations (defer drugs to ≥140/90): pre-treatment symptomatic orthostatic hypotension, age ≥85 years, moderate-to-severe frailty, limited lifespan <3 years (Class IIa, B)
• Target SBP: 120–129 mmHg in most adults (Class I, A); ALARA principle if not tolerated (Class I, A)
• Lenient target: <140 mmHg (symptomatic orthostasis or age ≥85, Class IIa, C); <140/90 (severe frailty or lifespan <3 years, Class IIb, C)

Treatment Thresholds — AHA 2025

• All adults SBP ≥140 or DBP ≥90: initiate antihypertensives (COR 1, LOE A). (sources/HT-AHA-2025, rating: very high)
• CVD, diabetes, CKD, or PREVENT ≥7.5%: initiate if SBP ≥130 or DBP ≥80 (COR 1, LOE A).
• PREVENT <7.5%: initiate if SBP ≥130/DBP ≥80 persists after 3–6 month lifestyle trial (COR 1).
• Goal for all: SBP <130 mmHg; encourage <120 mmHg if tolerated (COR 1 for high-risk; COR 2b for lower-risk).

BP Monitoring Modalities

• HBPM + cointerventions (telehealth, medication titration): COR 1, LOE A for monitoring treatment response. (sources/HT-AHA-2025, rating: very high)
• ABPM: Confirms white-coat and masked hypertension; nighttime BP provides additional CVD risk information.
• Cuffless devices and smartwatches: COR 3: No Benefit — insufficient validation for clinical use; PPG-based devices show skin tone bias; ISO validation standard (ISO 81060-7) still in development as of 2026. See concepts/Cuffless-BP-Monitoring for full technology assessment. (sources/cuffless-bp-aha-2026, rating: high)

Management

Lifestyle

• DASH eating plan: Most effective single lifestyle intervention; −5 to −8 mmHg SBP. (sources/HT-AHA-2025, rating: very high)
• Sodium: <2300 mg/d recommended; ideal <1500 mg/d; ~1 mmHg SBP per 1 mmol reduction.
• Potassium-based salt substitutes: COR 2a — useful for home food preparers; caution in CKD and with RAASi/K-sparing diuretics.
• Exercise: Aerobic + resistance + isometric exercise all lower BP; isometric exercise: −5 to −10 mmHg SBP.
• Alcohol: Optimal goal abstinence; SBP rises with any level of intake.
• Weight loss: ~1/1 mmHg SBP/DBP per kg lost; ≥5% body weight reduction for meaningful effect.

Pharmacological

• First-line agents: Thiazide-type diuretics, long-acting dihydropyridine CCB, ACEi, ARB. (sources/HT-AHA-2025, rating: very high)
• Stage 2 HT or high CVD risk: Start 2 agents as single-pill combination (SPC) — preferred over separate pills (COR 1, LOE A); improves adherence and reduces time to control.
• Avoid: ACEi + ARB combination (hyperkalemia, AKI risk); non-DHP CCB + BB (bradycardia risk).
• Beta-blockers: Not first-line for uncomplicated HT; preferred if concomitant CCD, HFrEF, or arrhythmia.
• Up to 50% of patients non-adherent at 1 year; once-daily SPC dosing improves adherence.

Resistant Hypertension

• Definition: BP above goal on ≥3 drugs of complementary mechanisms (including diuretic at max tolerated dose) OR at goal on ≥4 drugs. (sources/rnd-aha-2024, rating: high)
• Prevalence: 8.5–20% of hypertensive US adults; 50% higher risk of MI/stroke/ESKD vs non-resistant HT.
• Evaluate for: white-coat effect, non-adherence, interfering medications, secondary HT causes.
• 4th agent (COR 1): Spironolactone 25–50 mg/d (if eGFR ≥45 mL/min); reduces SBP 6.6–8.7 mmHg; superior to alpha-blocker or bisoprolol as 4th agent.
• Alternatives if MRA not tolerated: amiloride, beta-blockers, alpha-blockers, clonidine, aprocitentan (dual ERA).
• Aldosterone Synthase Inhibitors (ASIs) — emerging add-on therapy: Two agents have demonstrated efficacy in RCTs:
  • Baxdrostat (BaxHTN phase 3, n=794, NEJM 2025): 1 mg and 2 mg once daily reduced office SBP by −8.7 and −9.8 mmHg (placebo-corrected) in uncontrolled and resistant HT (P<0.001). (sources/baxdrostat-baxhtn-nejm-2025, rating: very high)
  • Lorundrostat (ADVANCE-HTN phase 2b, n=285, NEJM 2025): 50 mg stable dose reduced 24-hour ambulatory SBP by −7.9 mmHg (placebo-adjusted; P=0.001) at 12 weeks; dose-adjustment arm −6.5 mmHg (P=0.006); 50 mg is the optimal dose; 53% Black participants. Key safety note: lorundrostat inhibits the MATE1 renal transporter → serum creatinine rises spuriously; cystatin C should be used for renal monitoring. (sources/lorundrostat-advancehtn-nejm-2025, rating: high)
  • ASIs block aldosterone production (CYP11B2) rather than the receptor, avoiding MRA counter-regulatory increases in aldosterone; principal safety concerns are dose-dependent hyperkalemia (K >5.5–6.0: 6–11%), hyponatremia (~20% with baxdrostat), and a reversible eGFR dip. Not yet incorporated into guidelines (AHA 2025); no head-to-head comparison with spironolactone; no cardiovascular outcomes data. See concepts/Aldosterone-Synthase-Inhibitors.

Renal Denervation (RDN)

• ESC 2024 (major upgrade from Class III in 2018 to Class IIb in 2024):
  • Resistant HT (uncontrolled on 3-drug combination): Class IIb, B — medium-to-high volume centre; patient preference; multidisciplinary assessment (sources/ht-esc-2024, rating: very high)
  • Increased CVD risk + uncontrolled on <3 drugs (patient preference): Class IIb, A
  • Remains Class III: as first-line intervention; eGFR <40 or secondary HT causes
  • Key concern: ~6 mmHg office SBP reduction (= 1 drug equivalent); no CVD outcomes trial; not cost-effective vs generic pharmacotherapy
• AHA 2025 — COR 2b — adjunctive treatment for carefully selected patients after lifestyle + medication optimisation. (sources/HT-AHA-2025, rating: very high)
• FDA approval (Nov 2023): Medtronic Symplicity Spyral (radiofrequency) and Recor Medical Paradise (intravascular ultrasound). (sources/rnd-aha-2024, rating: high)
• Efficacy: 4.7–8.5 mmHg daytime SBP reduction vs sham in drug-naive patients; 60–70% achieve ≥5 mmHg reduction; ultrasound-based RDN outperforms radiofrequency (RADIOSOUND-HTN).
• vs Spironolactone: RDN inferior or equivalent to spironolactone as 4th agent (DENERVHTA, Prague-15); combination MRA + RDN not yet studied.
• Safety: No kidney function impairment; serious adverse events <1%; renal artery stenosis 0.2%/year; no late safety signals at 3 years. No CVD outcomes trial data.

See concepts/Renal-Denervation for full procedure detail, device types, complete trial data, patient selection framework, and contraindications.

Secondary Hypertension

• Present in 5–25% of cases (10–35% per ESC 2024); more common with resistant HT, Stage 2 HT, early onset.
• Most common causes: OSA (25–50% of resistant HT), primary aldosteronism (up to 12% at BP >180/110 mmHg), CKD, drug-induced, renovascular HT.
• ESC 2024 — ALL confirmed hypertensive patients: Screen with aldosterone-to-renin ratio (ARR) for primary aldosteronism (Class IIa, B) — not just resistant HT; hypokalemia absent in majority. (sources/ht-esc-2024, rating: very high)
• AHA 2025 — Resistant HT only: Screen for primary aldosteronism regardless of hypokalemia (COR 1, LOE B-NR). (sources/HT-AHA-2025, rating: very high)
• ARR interpretation varies with concurrent medications; beta-blockers, central agents, RAS blockers, and diuretics interfere (ESC 2024 Table 12); long-acting CCBs and alpha-blockers do not
• Continue most antihypertensives (except MRA) during initial aldosterone/renin screening if stopping not feasible.

Comorbidities

• Diabetes: ACEi/ARB recommended if eGFR <60 or albuminuria ≥30 mg/g (COR 1, upgraded from COR 2b); SBP goal <130 mmHg; encourage <120 mmHg if tolerated (COR 2b). (sources/HT-AHA-2025, rating: very high) — BPROAD trial (NEJM 2025; n=12,821 Chinese T2DM patients ≥50 years) now provides first adequately-powered RCT evidence: intensive SBP <120 mmHg vs standard <140 mmHg reduced major CVD events by 21% (HR 0.79; 95% CI 0.69–0.90; P<0.001); stroke HR 0.79; albuminuria HR 0.87; serious AEs equivalent; hyperkalemia 2.8% vs 2.0% requires monitoring. (sources/bp-dm-bproad-nejm-2025, rating: very high) See concepts/Blood-Pressure-Target-T2DM.
• CKD: SBP goal <130 mmHg; RAASi (ACEi or ARB, not both) if albuminuria ≥30 mg/g; eGFR dip ≤30% acceptable.
• Atrial fibrillation: HT has highest attributable risk for AF; BP goal <130/80 mmHg reduces AF incidence and MACE.
• HF prevention: HT antecedent in 71% of HF; SBP <130 mmHg reduces HF incidence.
• HFrEF: Uptitrate GDMT (ARNi/ACEi/ARB + BB + MRA + SGLT2i) as first-line BP strategy; add dihydropyridine CCB if needed; avoid non-DHP CCB (COR 3 Harm). See entities/HFrEF.
• HFpEF: RAASi (ARNi/MRA/ARB) preferred; SGLT2i; diuretics for volume; BB NOT recommended for BP control (negative chronotropy impairs diastolic filling). (sources/HT-AHA-2025, rating: very high)
• Dementia prevention: SBP goal <130 mmHg — COR 1 (upgraded from COR 2a); SPRINT-MIND legacy data show 7-year benefit. (sources/HT-AHA-2025, rating: very high)
• Aortic disease: BP <130/80 mmHg; BB preferred; abdominal aortic aneurysm rupture risk +30% per 10 mmHg.
• PAD: SBP <130/80 mmHg; ACEi/ARB first-line; no evidence antihypertensives worsen claudication.

Stroke

• Acute ICH (SBP 150–220 mmHg): Lower to 130–<140 mmHg for ≥7 days; avoid SBP <130 mmHg (COR 2a). (sources/HT-AHA-2025, rating: very high)
• Post-EVT reperfusion (large vessel occlusion) — SBP <140 mmHg within 72h — COR 3: HARM: ENCHANTED2/MT trial — intensive lowering to <140 mmHg after successful EVT (mTICI 2b/2c/3) increased death and disability; optimal post-EVT target is 140–180 mmHg for ≥72h. (sources/ais-aha-2026, rating: very high)
• Post-IVT (no EVT): Maintain <180/105 mmHg; SBP <140 mmHg target post-IVT — COR 3: No Benefit. (sources/ais-aha-2026, rating: very high)
• Secondary stroke prevention: SBP/DBP goal <130/80 mmHg (COR 1); thiazide/ACEi/ARB preferred. (sources/HT-AHA-2025, rating: very high)
• See entities/Ischemic-Stroke for full AIS management including EVT selection, thrombolysis, and acute BP targets.

Pregnancy

• Severe acute HT (≥160/110 mmHg): Treat to <160/110 mmHg within 30–60 min (COR 1). (sources/ht-pregnancy-aha-2022, rating: high)
• Chronic HT: Treat to <140/90 mmHg (COR 1) — CHAP trial confirmed treating mild chronic HT reduces adverse pregnancy outcomes without increasing SGA.
• Preeclampsia prevention: Low-dose aspirin 81–150 mg/day from 12–16 weeks for high-risk women (≥1 high or ≥2 moderate risk factors); reduces preeclampsia by 10–20%. (sources/ht-pregnancy-aha-2022, rating: high)
• Contraindicated (COR 3: Harm): Atenolol (fetal growth restriction), ACEi, ARB, direct renin inhibitors (fetal renal development), nitroprusside, MRA/spironolactone (antiandrogenic).
• Safe first-line agents: Labetalol, long-acting nifedipine, methyldopa — equivalent per Cochrane review. Severe acute HT: parenteral labetalol, parenteral hydralazine, or oral nifedipine — comparable.
• Controversy: US ACOG threshold ≥160/110 mmHg vs international consensus ≥140/90 mmHg; CHIPS trial supports tighter control (achieved 133/85 mmHg) without adverse fetal outcomes. (sources/ht-pregnancy-aha-2022, rating: high)
• Postpartum: ~60% of maternal deaths occur in first year postpartum; furosemide RCT: 60% reduction in persistent postpartum HT at day 7.
• History of HDP (long-term risk): Sex-specific CVD risk enhancer — HF HR 2.7, stroke HR 1.9, ESKD RR 6.6 after preeclampsia; annual BP/CVD risk assessment; early CVD risk factor control.
• See concepts/Hypertensive-Disorders-of-Pregnancy and concepts/Preeclampsia for full HDP detail.

Contradictions / Open Questions

• ESC 2024 vs AHA 2025 — BP classification mismatch: ESC uses "elevated BP" for SBP 120–139/DBP 70–89 with the same lower threshold (120/70 mmHg) for both; AHA uses "elevated" for SBP 120–129 with DBP <80 mmHg only. A patient with SBP 125/DBP 82 mmHg is "elevated BP" by ESC but "Stage 1 hypertension" by AHA — producing different treatment thresholds. (sources/ht-esc-2024, rating: very high; sources/HT-AHA-2025, rating: very high)
• ESC 2024 vs AHA 2025 — Treatment target conflict: ESC mandates SBP 120–129 mmHg as a single Class I, A target for most adults; AHA lists <130 mmHg as the primary COR 1 goal with <120 mmHg as COR 2b. ESC's rationale is to eliminate the 130–139 mmHg intermediate zone that drives therapeutic inertia. (sources/ht-esc-2024, rating: very high; sources/HT-AHA-2025, rating: very high)
• Primary aldosteronism screening threshold: ESC 2024 recommends ARR screening in ALL confirmed hypertensive patients; AHA 2025 limits to resistant HT only. Current real-world screening rates ~2% of eligible patients — universal ESC screening aspirational without system-level implementation. (sources/ht-esc-2024, rating: very high)
• PREVENT vs ASCVD-only tools: PREVENT estimates total CVD (adds HF) whereas ASCVD-focused guidelines (cholesterol) still use ASCVD-only outputs — creates potential risk category mismatches for the same patient. (sources/HT-AHA-2025, rating: very high)
• Intensive BP target in T2DM (<120 mmHg): BPROAD (NEJM 2025; HR 0.79; P<0.001) definitively resolves ACCORD null result (HR 0.88; underpowered; factorial confound); first RCT support for SBP <120 mmHg over <140 mmHg in T2DM. Guideline <130 mmHg recommendation predated this evidence — update expected. (sources/bp-dm-bproad-nejm-2025, rating: very high)
• Optimal BP target in HFpEF: No RCT data directly establishing BP target; extrapolated from general hypertension trials.
• DBP J-curve: Post-hoc SPRINT data suggest J-curve for DBP and coronary events; no fixed lower limit established in RCTs; clinical monitoring recommended.
• RDN efficacy: Inconsistent across trials — early negative trials (SYMPLICITY HTN-3, REDUCE HTN:REINFORCE) vs positive newer trials with improved technique and standardised drug surveillance; no CVD outcomes data; inferior or equivalent to spironolactone as 4th agent in resistant HT. (sources/rnd-aha-2024, rating: high)
• RDN vs spironolactone sequencing: Should spironolactone always precede RDN in resistant HT? Combination MRA + RDN not yet studied.
• Aldosterone synthase inhibitors vs MRAs: BaxHTN (n=794, NEJM 2025) and ADVANCE-HTN (n=285, NEJM 2025) demonstrate ~7–10 mmHg placebo-corrected SBP reduction with baxdrostat/lorundrostat, comparable to spironolactone's 6.6–8.7 mmHg effect in resistant HT. However: (1) no head-to-head RCT compares ASIs with spironolactone; (2) no cardiovascular outcomes data exist for ASIs; (3) ASIs are not yet guideline-recommended. Whether ASIs should replace, precede, or supplement MRAs as add-on therapy in resistant HT is unresolved. Cross-trial comparisons of lorundrostat vs baxdrostat effect sizes are also confounded by different BP measurement methods (ambulatory vs office). (sources/baxdrostat-baxhtn-nejm-2025, rating: very high; sources/lorundrostat-advancehtn-nejm-2025, rating: high)
• RDN reinnervation in humans: Animal models show partial/full reinnervation with persistent BP reduction; human durability data from registries only (no long-term sham-controlled data).
• Post-kidney transplant BP: No robust RCT evidence for specific targets or drug class preference.
• Asleep BP: Unclear whether isolated nocturnal hypertension (high asleep, normal awake BP) warrants treatment; no high-quality RCT evidence.

Connections

• Related to concepts/Hypertension-HMOD — HMOD assessment framework; triggers treatment in elevated BP category
• Related to concepts/ASCVD-Risk-Assessment — PREVENT™ replaces PCEs; total CVD estimation
• Related to entities/Atrial-Fibrillation — highest attributable risk for new-onset AF
• Related to entities/Heart-Failure — antecedent in 71% HF; BP management across HF phenotypes
• Related to entities/HFrEF — GDMT-first BP strategy; non-DHP CCB contraindicated
• Related to entities/HFpEF — HT as major HFpEF driver; BB not for BP control in HFpEF
• Related to entities/Obstructive-Sleep-Apnea — secondary HT; 25–50% prevalence
• Related to concepts/LV-Diastolic-Function — hypertension → LVH → diastolic dysfunction
• Related to concepts/Cuffless-BP-Monitoring — 2025/2026 AHA position: not recommended for clinical use
• Related to entities/Ischemic-Stroke — post-EVT BP harm; secondary stroke prevention targets
• Related to concepts/Renal-Denervation — catheter-based adjunctive treatment for resistant/uncontrolled HT
• Related to concepts/Hypertensive-Disorders-of-Pregnancy — BP thresholds and targets in pregnancy
• Related to concepts/Preeclampsia — strongest independent predictor of future hypertension (OR 11.6)
• Related to concepts/Blood-Pressure-Target-T2DM — first RCT evidence for SBP <120 mmHg in T2DM
• Related to entities/Type-2-Diabetes — most common HTN comorbidity; BPROAD defines BP target
• Related to concepts/Aldosterone-Synthase-Inhibitors — emerging add-on therapy for resistant/uncontrolled HT; BaxHTN ~9 mmHg office SBP (NEJM 2025); ADVANCE-HTN −7.9 mmHg 24h ambulatory SBP (NEJM 2025)

Sources

• sources/ht-esc-2024
• sources/HT-AHA-2025
• sources/ais-aha-2026
• sources/cuffless-bp-aha-2026
• sources/ht-pregnancy-aha-2022
• sources/rnd-aha-2024
• sources/bp-dm-bproad-nejm-2025
• sources/baxdrostat-baxhtn-nejm-2025
• sources/lorundrostat-advancehtn-nejm-2025